← Leaderboards
Steven P Rowe
Johns Hopkins University
$1,307,572
Attributed
$2,615,144
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $693.8K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,615,144 · 1
By mechanism
R01$2,615,144 · 1
Top collaborators
- Sridhar Nimmagadda4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Tza-Huei Jeff Wang$29,391,444
- Martin G Pomper$38,517,075
- Kristine Glunde$12,806,818
- Daniel Lyndon Jaffe Thorek$4,988,087
- Sinisa Urban$8,866,210
Others in their field
Other Rising Stars on “Affinity”
- Jason Dickens · Duke University$12,259,409
- Jeff T Hutchins · Inhalon Biopharma, Inc.$8,734,904
- Joseph Fraser Glickman · Hackensack University Medical Center$8,363,749
- Mark Sorenson · Nirsum Laboratories, Inc.$4,866,388
- Michael P Weiner · Abbratech, Inc.$4,404,422
- Moustafa Gabr · Weill Medical Coll Of Cornell Univ$3,945,669
Research focus
AffinityBiologicalBiological MarkersBiomarker PanelBiopsyCancer CareCancer ImmunotherapyCancer ModelCancer PatientCheckpoint TherapyChemistryClinicClinical ApplicationClinical ManagementClinical TranslationClinical TrialsCollaborationsContrast ImagingDesignDetectionDosimetryEffectivenessEvaluationExcipients
Grant awards (4)
Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancers$693,779
R01 · FY2025 · CA
Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancers$635,583
R01 · FY2024 · CA
Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancers$660,982
R01 · FY2023 · CA
Clinical translation of a PD-L1 PET tracer to optimize immune checkpoint therapy in patients with non-small cell lung cancers$624,800
R01 · FY2022 · CA